1. George D. Demetri Graduated: Stanford Medical School Residency: Univ. of Washington Hospitals Internal Medicine Fellowship: Dana Farber Cancer Institute, Hematology & Oncology, Boston Board certification Internal Medicine 1986 Board certification Oncology 1989 Professor of Medicine,Harvard Medical School Director, Center of Sarcoma and Bone Oncology, DFCI Director of the Ludwig Center Senior Vice President of Experimental Therapeutics PubMed 265 publications

2. Drug development in sarcoma  Imatinib  Sunitinib  Regorafenib  Nilotinib  Retaspymicin  Ridaforolimus  Trabectedin  Tivantinib  Efatutazone  Conatumumab  Everolimus  CDK4 inhibitors  Dasatinib flagship of innovation in soft tissue sarcoma

3. George D. Demetri ‘Creative, high speed lab’ George and Jaap Verweij wrote the protocol for phase III for imatinib in metastatic GIST (SWOG-033 and EORTC 62005) overnight from October 31 – November 1, 2000. This study marked the start of an intensified contact between US and EU sarcoma researchers. Start of very much improved collaboration between US and EORTC and for the setup of Worls´d SarcomaNetwork (WSN). Example of an international oriented researcher who will always seek collaboration Surplus

5. Now and here